TY - JOUR
T1 - Gastric adenomas and their management in familial adenomatous polyposis
AU - Martin, Isabel
AU - Roos, Victorine H.
AU - Anele, Chukwuemeka
AU - Walton, Sarah-Jane
AU - Cuthill, Victoria
AU - Suzuki, Noriko
AU - Bastiaansen, Barbara A.
AU - Clark, Susan K.
AU - von Roon, Alexander
AU - Dekker, Evelien
AU - Latchford, Andrew
N1 - Funding Information: Prof. Dekker has received a research grant and equipment loans from FujiFilm. She has also received honoraria for consultancy work for Fu-jiFilm, Olympus, Tillots, GI Supply, and CPP-FAP, and speaker fees from Olympus, Roche, and GI supply. All other authors declare that they have no conflicts of interest. Publisher Copyright: © 2021 Georg Thieme Verlag. All rights reserved.
PY - 2021/8/1
Y1 - 2021/8/1
N2 - Background Patients with familial adenomatous polyposis (FAP) are at increased risk of developing gastric adenomas. There is limited understanding of their clinical course and no consensus on management. We reviewed the management of gastric adenomas in patients with FAP from two centers. Methods Patients with FAP and histologically confirmed gastric adenomas were identified between 1997 and 2018. Patient demographics, adenoma characteristics, and management/surveillance outcomes were collected. Results Of 726 patients with FAP, 104 (14%; 49 female) were diagnosed with gastric adenomas at a median age of 47 years (range 19-80). The median size of gastric adenomas was 6mm (range 1.5-50); 64 (62%) patients had adenomas located distally to the incisura. Five patients (5%) had gastric adenomas demonstrating high-grade dysplasia (HGD) on initial diagnosis, distributed equally within the stomach. The risk of HGD was associated with adenoma size (P =0.04). Of adenomas>20mm, 33% contained HGD. Two patients had gastric cancer at initial gastric adenoma diagnosis. A total of 63 patients (61%) underwent endoscopic therapy for gastric adenomas. Complications occurred in three patients (5%) and two (3%) had recurrence, all following piecemeal resection of large (30-50mm) lesions. Three patients were diagnosed with gastric cancer at median follow-up of 66 months (range 66-115) after initial diagnosis. Conclusions We observed gastric adenomas in 14% of patients with FAP. Of these, 5% contained HGD; risk of HGD correlated with adenoma size. Endoscopic resection was feasible, with few complications and low recurrence rates, but did not completely eliminate the cancer risk.
AB - Background Patients with familial adenomatous polyposis (FAP) are at increased risk of developing gastric adenomas. There is limited understanding of their clinical course and no consensus on management. We reviewed the management of gastric adenomas in patients with FAP from two centers. Methods Patients with FAP and histologically confirmed gastric adenomas were identified between 1997 and 2018. Patient demographics, adenoma characteristics, and management/surveillance outcomes were collected. Results Of 726 patients with FAP, 104 (14%; 49 female) were diagnosed with gastric adenomas at a median age of 47 years (range 19-80). The median size of gastric adenomas was 6mm (range 1.5-50); 64 (62%) patients had adenomas located distally to the incisura. Five patients (5%) had gastric adenomas demonstrating high-grade dysplasia (HGD) on initial diagnosis, distributed equally within the stomach. The risk of HGD was associated with adenoma size (P =0.04). Of adenomas>20mm, 33% contained HGD. Two patients had gastric cancer at initial gastric adenoma diagnosis. A total of 63 patients (61%) underwent endoscopic therapy for gastric adenomas. Complications occurred in three patients (5%) and two (3%) had recurrence, all following piecemeal resection of large (30-50mm) lesions. Three patients were diagnosed with gastric cancer at median follow-up of 66 months (range 66-115) after initial diagnosis. Conclusions We observed gastric adenomas in 14% of patients with FAP. Of these, 5% contained HGD; risk of HGD correlated with adenoma size. Endoscopic resection was feasible, with few complications and low recurrence rates, but did not completely eliminate the cancer risk.
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85096065855&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/32942317
U2 - https://doi.org/10.1055/a-1265-2716
DO - https://doi.org/10.1055/a-1265-2716
M3 - Article
C2 - 32942317
SN - 0013-726X
VL - 53
SP - 795
EP - 801
JO - Endoscopy
JF - Endoscopy
IS - 8
ER -